| 白三烯受体拮抗剂治疗原发性鼾症的临床疗效观察 |
| 投稿时间：2015-04-02 修订日期：2015-04-30 点此下载全文 |
| 引用本文：俞晨艺,李秀翠,曹顺顺,潘丽萍,苏苗赏,蔡晓红.白三烯受体拮抗剂治疗原发性鼾症的临床疗效观察[J].医学研究杂志,2015,44(12):63-66 |
| DOI：
10.11969/j.issn.1673-548X.2015.12.017 |
| 摘要点击次数: 847 |
| 全文下载次数: 874 |
|
| 基金项目:国家卫生和计划生育委员会国家重点临床专科开放课题(20130201);浙江省自然科学基金资助项目(Y2110277);浙江省科技厅基金资助项目(2008C33011);浙江省科技厅公益性技术应用研究计划项目(2013C33174);浙江省医药卫生科技计划(2014ZDA014);浙江省高等教育研究课题(KT2014064) |
|
| 中文摘要:目的评估白三烯受体拮抗剂治疗原发性鼾症(PS)儿童的临床疗效。方法选择2008年3月~2010年12月经多导睡眠监测(PSG)诊断PS儿童65例,随机分为治疗组33例,对照组32例。治疗组予白三烯受体拮抗剂治疗,治疗前进行PSG监测、鼾症儿童生活质量调查表(OSA-18)评分,治疗6个月后复查,并登记复诊资料及检查结果;对照组未予治疗,初诊时予以PSG监测、OSA-18评分,6个月随访时再次进行OSA-18评分。结果治疗组PSG监测治疗前后比较差异均无统计学意义(P > 0.05),但OSA-18评分治疗后儿童睡眠障碍(治疗前12.85±5.10,治疗后8.15±2.97,Z=-3.83,P<0.05)、身体症状(治疗前11.82±5.35,治疗后8.12±3.25,Z=-2.96,P<0.05)、对监护人影响(治疗前10.33±4.43,治疗后6.69±2.99,Z=-3.27,P<0.05)、OSA-18总分(治疗前47.73±15.63,治疗后33.94±9.40,Z=-3.53,P<0.05)较治疗前好转,差异有统计学意义。对照组随访前后OSA-18评分比较差异无统计学意义(P>0.05)。治疗组治疗后睡眠障碍较对照组明显改善,差异有统计学意义(治疗组8.15±2.97,对照组11.38±5.63,Z=-2.20,P<0.05)。结论白三烯受体拮抗剂能改善PS儿童生活质量。 |
| 中文关键词:原发性鼾症 儿童 白三烯 |
| |
| A Study on Efficiency of Leukotriene Receptor Antagonist Used for Treating Primary Snoring in Children. |
|
|
| Abstract:Objective To evaluate effectiveness of Leukotriene receptor antagonist treatment in primary snoring(PS) children. Methods The study was performed from Mar 2008 to Dec 2010. The main objects were the 65 cases who were diagnosed as PS monitored by polysomnography (PSG). Thirty three children with PS were divided into treatment group which group were treated with leukotriene receptor antagonists, 32 children in control group were left untreated. The treatment group were evaluated by PSG and quality of life for children with Obstructive Sleep Apnea-18(OSA-18) items before and after a six-month treatment. Both records were taken. The control group were interviewed with PSG and OSA-18 items, and evaluated by OSA-18 items after a six month follow-up. Results There was no significant difference in PSG was observed before and after treatment in the treatment group with PS (P>0.05). In the treatment group, significant differences were found in sleeping disorder (before receiving the treatment 12.85±5.10, and after receiving the treatment 8.15±2.97, Z=-3.83,P<0.05), body symptoms (before receiving the treatment 11.82±5.35, and after receiving the treatment 8.12±3.25,Z=-2.96,P<0.05), the degree of familial stress (before receiving the treatment 10.33±4.43, and after receiving the treatment 6.69±2.99,Z=-3.27,P<0.05), and OSA-18 total scores (before receiving the treatment 47.73±15.63, and after receiving the treatment 33.94±9.40,Z=-3.53,P<0.05). There was no significant difference in OSA-18 items was observed before and after follow-up in the control group with PS (P>0.05). There were significant differences between two groups in the sleeping disorder (the treatment group 8.15±2.97, and the control group 11.38±5.63, Z=-2.20,P<0.05), and treatment group had significant improvement. Conclusion Leukotriene receptor antagonist could improve the quality of life in the children with PS. |
| keywords:Primary snoring Child Leukotrienes |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
